NICE rejection of Afinitor faces appeal from Novartis
This article was originally published in Scrip
Executive Summary
Novartis is the second pharmaceutical company this week to announce plans to appeal against NICE, the health technology institute for England and Wales. Today NICE is publishing its second final draft guidance rejecting Afinitor (everolimus) for some patients with advanced kidney cancer, despite the company submitting a revised patient access scheme. Novartis says the interim cancer drugs fund is the best hope for patients who need to access the drug.